Gala Health Reviews: The $179 Is a Yearly Rate

The one-sentence version

Gala Health — the site brands itself Gala GLP-1 — puts "$179/mo all doses, no hidden fees" at the top of its homepage, then prints the footnote that undoes it: "Price calculated based on a yearly subscription plan." Its own FAQ quotes a different and higher entry point. No month-to-month price is published anywhere on the site, which is why it scores 4 points out of 14 — the lowest grade on this board. The second reason is that it is not really a longevity provider: no NAD+, no sermorelin, no peptide and no diagnostic line, only compounded GLP-1s and menopause hormones. The grade is computed from published terms alone and cannot see who pays us.

What it is, and who it's for

Gala is a GLP-1 telehealth operator with licensed providers in all 50 states, run by AI Coaching, Inc., with medical care delivered by "licensed physicians and clinicians affiliated with independently owned and operated medical practices, including OpenLoop-affiliated medical groups." Gala itself "provides administrative, technology, and management services and does not provide medical care."

The catalogue is four items and a menopause menu: compounded GLP-1/GIP including tirzepatide, a low-dose "microdosing" tier the navigation labels a "Low-dose longevity protocol", brand-name Ozempic, and an oral GLP-1 marked coming soon. The hormone shelf is estradiol pill or patch, progesterone, vaginal estradiol and non-hormonal options for hot flashes and night sweats.

That is a competent weight-loss and menopause service. It is not a longevity clinic — if you arrived looking for one, start with what a longevity clinic actually costs.

What it actually costs

All figures verified on galaglp1.com on 26 July 2026.

The headline. The hero reads "$179/mo all doses, no hidden fees." The treatments grid repeats it as "$179/month" for compounded GLP-1/GIP and "$149/month" for the microdosing tier, each carrying an asterisk. Brand Ozempic is "$1,299/month", stated flat.

The asterisk. Directly beneath that grid: *"Compounded GLP-1 is not FDA-approved and is sourced from licensed compounding pharmacies. Price calculated based on a yearly subscription plan."* So $179 and $149 are twelve-month rates. "No hidden fees" and the footnote that redefines the fee sit on the same page.

The FAQ quotes something else again. "Through Gala GLP-1, you can access GLP-1 weight loss medications (not-FDA approved) starting at just $199 per month (with a 3-month plan). Final pricing is determined at checkout based on your selected plan and medication." That is the cheapest figure Gala publishes with a term attached — and it is $20 above the number on the homepage, on a shorter commitment.

Nothing states the monthly price. Not the homepage, not the treatments grid, not the FAQ. And Gala's own cancellation policy makes clear that monthly billing exists: "you will be charged for the first month of the Subscription Services", with "a cancellation request… received at least 72 hours prior to your billing date." There is a monthly cadence. Its price is simply never printed.

What cancelling costs. You may "cancel your Subscription Service at any time for any reason" with that 72-hour notice. But the same policy states that other than cancellation for medical disqualification, "IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION OF THE SUBSCRIPTION SERVICES", and any approved refund covers "your most recent billing cycle" only. Beside a yearly headline rate, that is the term to understand before choosing a plan length.

What Gala does well

Two things, and they are real. Dose increases are free — if a higher dose is recommended "it will be available at no additional cost", and if a medication is not working "your provider can adjust your prescription at no additional cost." In a category where titration routinely reprices a plan, that is genuine protection. And a provider is included: consultations may be "synchronous—such as a video visit—or asynchronous, like online messaging", with messaging at no extra cost. That earns its oversight points in full.

Where it earns nothing is pharmacy. Asked which pharmacies it partners with, Gala answers "we work with a wide network of pharmacies across all 50 states" — no name, no address, no 503A or 503B classification. FDA's position on what that leaves open is blunt: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed¹.

The evidence behind what it sells

Gala's hero carries a stat block reading "20% weight loss in 6 months", footnoted to "clinical studies of GLP-1 medications combined with lifestyle changes."

The trial that produced a 20% figure is SURMOUNT-1, which randomised 2,539 adults with obesity to tirzepatide or placebo. Mean weight change at week 72 was −15.0% on 5 mg, −19.5% on 10 mg and −20.9% on 15 mg, against −3.1% on placebo². Week 72 is roughly seventeen months, including a twenty-week dose-escalation period. The drug is real and the effect is real — this is one of the few things sold on this board with hard randomised outcome data behind it. But 20% is not a six-month result at any dose.

The "longevity protocol" is the weaker claim. Gala's microdosing tier is a sub-therapeutic GLP-1 dose marketed as longevity care. The doses with outcome evidence are the trial doses — 5, 10 and 15 mg² — and no completed trial has tested a GLP-1 microdose against any aging endpoint. Labelling a lower dose "longevity" is positioning, not a finding. See GLP-1s for longevity and what's proven versus hyped.

One point in Gala's favour: the NAD+ and peptide lines it lacks are not lines with better evidence. The 2026 PRISMA-guided systematic review of NAD+ screened 113 studies including 33 human trials, found clinical effectiveness "inconclusive", and reported that no eligible outcomes trial has evaluated injected NAD+ for these indications at all³. Gala is marked down for not selling that shelf because this board ranks longevity providers — not because the shelf works. See NAD+ for longevity.

Where it's weak, and who should skip it

Skip it if you are shopping for longevity medicine: there is no NAD+, no sermorelin, no peptide and no biomarker panel here, and the "longevity protocol" is a smaller dose of a weight-loss drug. Skip it if you need to know the price of one month before committing, because that number does not exist on the site. And do not read "no hidden fees" as "no terms" — the fee is not hidden, the term is.

If you proceed: make Gala quote you the monthly and three-month rates in writing before you pick a plan, and understand that cancelling stops future billing but does not refund what you have already paid.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Gala takes two of the four longevity-line points, not zero — menopause hormone therapy and a self-declared longevity microdose put it adjacent to what this board ranks rather than on it — and two for a provider inside the price. It takes zero on price transparency, because the advertised figure is a yearly rate, the FAQ's cheapest quote is a different and higher number on a different term, and no monthly price is published at all. Zero on pharmacy, and zero on human support. Four out of fourteen: a C, and the lowest score on the board. The owner of this site has seen that grade and let it stand.

The remedy is one line of HTML. Publish the month-to-month price beside the yearly one, and Gala jumps straight out of last place — the medicine, the fifty-state coverage and the free dose increases are already there. Our other two C-graded partners are in the MadeMed review and the Try Ageless review; the full field is at our provider rankings and the scoring is set out in how we grade.